Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785879 | 0.92 | CTSS (0.42) | F10CTSSMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL785136 | 0.87 | F10 (0.38) | F10CTSSNPY5R | |
| SCHEMBL785701 | 0.87 | TAS1R3 (0.41) | F10CTSSMEN1KMT2ALMNA | |
| SCHEMBL784572 | 0.86 | F10 (0.39) | F10CTSSNPY5R | |
| SCHEMBL784713 | 0.86 | F10 (0.42) | F10NPY5R | |
| SCHEMBL785726 | 0.85 | TAS1R3 (0.41) | F10CTSSMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL785032 | 0.85 | F10 (0.41) | F10SMN1; SMN2LMNA | |
| SCHEMBL785734 | 0.84 | CTSS (0.44) | F10CTSSSMN1; SMN2MAPT | |
| SCHEMBL784957 | 0.82 | CTSS (0.43) | F10CTSSSMN1; SMN2LMNAMAPT | |
| SCHEMBL784203 | 0.82 | ALDH1A1 (0.51) | CTSSMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | F10 524/4885CTSS 824/4885NPY5R 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.